Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1303002

USP

Haloperidol

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H23ClFNO2
CAS Number:
52-86-8
Molecular Weight:
375.86
MDL number:
MFCD00051423
UNSPSC Code:
41116107
PubChem Substance ID:
329749983
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

haloperidol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3

InChI

1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

InChI key

LNEPOXFFQSENCJ-UHFFFAOYSA-N

Gene Information

human ... HTR2A(3356)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Haloperidol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Cisapride
  • Haloperidol
  • Haloperidol Injection
  • Haloperidol Oral Solution
  • Haloperidol Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

H0100000

Haloperidol, European Pharmacopoeia (EP) Reference Standard

H0100100

Haloperidol decanoate, European Pharmacopoeia (EP) Reference Standard

Y0001517

Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001518

Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard

1303013

Haloperidol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1303057

Haloperidol decanoate, United States Pharmacopeia (USP) Reference Standard

1303024

Haloperidol Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP407

Haloperidol, British Pharmacopoeia (BP) Reference Standard

PHR8951

Haloperidol Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8714

Haloperidol Related Compound B, certified reference material, pharmaceutical secondary standard

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Alprazolam Related Compound A United States Pharmacopeia (USP) Reference Standard

USP

1015019

Alprazolam Related Compound A

Mark C Fok et al.
International journal of geriatric psychiatry, 30(4), 333-344 (2015-02-03)
To summarize the effect of antipsychotics for preventing postoperative delirium. We conducted a literature search using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and clinicaltrials.gov. We included randomized controlled trials of adults undergoing surgery
Marianne Klemp et al.
Journal of clinical psychopharmacology, 31(6), 698-704 (2011-10-25)
The objective of the study was to examine the efficacy and the degree of adverse effects connected with atypical neuroleptic drugs and haloperidol by using a previously described Bayesian statistical method that includes both direct and indirect comparisons simultaneously. The
Paul Perkins et al.
The Cochrane database of systematic reviews, (2)(2), CD006271-CD006271 (2009-04-17)
Nausea and vomiting are common symptoms of patients with terminal, incurable illnesses and can be distressing. The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of
Gerard W K Hugenholtz et al.
The Journal of clinical psychiatry, 67(6), 897-903 (2006-07-20)
To determine the doses of haloperidol as a comparator drug in randomized controlled trials (RCTs) with atypical antipsychotics in patients with schizophrenia and to compare these doses with the officially recommended doses for haloperidol in the United States and the
Jan Booij et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(4), 647-649 (2014-03-08)
A recent (123)I-FP-CIT ((123)-I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane) SPECT study on rats suggested that a single 1 mg/kg dose of the antipsychotic haloperidol induces enough dopamine release to compete with (123)I-FP-CIT for binding to the dopamine transporter. Taking into account the far-reaching consequences of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service